Inventor · disambiguated record
Gregory E. Hardee
Also filed as: HARDEE GREGORY · HARDEE GREGORY E
10 granted patents·10 pending applications·612 citations·filing 1994–2019
92Inventor score
Files withISIS PHARMACEUTICALS INC10DEAN NICHOLAS M2DOKKA SUJATHA1EXCALIARD PHARMACEUTICALS INC1UPJOHN CO1
Top patents by PatentIndex Score
20 records- 0198US6747014B2Compositions and methods for non-parenteral delivery of oligonucleotidesISIS PHARMACEUTICALS INC·Filed 2001·Granted Jun 8, 2004·356 cites·10 claims
- 0297US8691785B2Compositions and methods for non-parenteral delivery of oligonucleotidesISIS PHARMACEUTICALS INC·Filed 2013·Granted Apr 8, 2014·48 cites·13 claims
- 0395US5721359ACrystalline ceftiofur free acidUPJOHN CO·Filed 1994·Granted Feb 24, 1998·92 cites·24 claims
- 0488US7964579B2Compositions and methods for topical delivery of oligonucleotidesISIS PHARMACEUTICALS INC·Filed 2009·Granted Jun 21, 2011·4 cites·43 claims
- 0585US8168600B2Compositions and methods for topical delivery of oligonucleotidesDOKKA SUJATHA·Filed 2005·Granted May 1, 2012·19 cites·21 claims
- 0684US6841539B1Compositions and methods for topical delivery of oligonucleotidesISIS PHARMACEUTICALS INC·Filed 1999·Granted Jan 11, 2005·52 cites·1 claims
- 0783US8377897B2Compositions and methods for non-parenteral delivery of oligonucleotidesISIS PHARMACEUTICALS INC·Filed 2005·Granted Feb 19, 2013·6 cites·9 claims
- 0881US7576067B2Pulsatile release compositions and methods for enhanced intestinal oligonucleotide drug absorptionISIS PHARMACEUTICALS INC·Filed 2004·Granted Aug 18, 2009·16 cites·25 claims
- 0965US9173894B2Method of treating keloids or hypertrophic scars using antisense compounds targeting connective tissue growth factor (CTGF)DEAN NICHOLAS M·Filed 2012·Granted Nov 3, 2015·1 cites·27 claims
- 1064US2020190521A1Method of treating keloids or hypertrophic scars using antisense compounds targeting connective tissue growth factor (ctgf)DEAN NICHOLAS M·Filed 2019·Application pending·0 cites
- 1163US2005096287A1Compositions and methods for topical delivery of oligonucleotidesFiled 2004·Application pending·0 cites
- 1261US2011256217A1Pulsatile release compositions and methods for enhanced intestinal drug absorptionISIS PHARMACEUTICALS INC·Filed 2009·Application pending·0 cites
- 1357US2004229831A1Compositions and methods for non-parenteral delivery of oligonucleotidesISIS PHARMACEUTICALS INC·Filed 2004·Application pending·0 cites
- 1456US6083923ALiposomal oligonucleotide compositions for modulating RAS gene expressionISIS PHARMACEUTICALS INC·Filed 1997·Granted Jul 4, 2000·18 cites·4 claims
- 1555US2005002999A1Long-circulating liposomal compositionsFiled 2004·Application pending·0 cites
- 1653US2011213014A1Compositions and methods for topical delivery of oligonucleotidesISIS PHARMACEUTICALS INC·Filed 2011·Application pending·0 cites
- 1747US2003027780A1Multiparticulate formulationFiled 2002·Application pending·0 cites
- 1845US2003124196A1Pulsatile release compositions and methods for enhanced intestinal drug absorptionFiled 2001·Application pending·0 cites
- 1938US2003083286A1Bioadhesive compositions and methods for enhanced intestinal drug absorptionFiled 2001·Application pending·0 cites
- 2037US2017022501A1Method of treating keloids or hypertrophic scars using antisense compounds targeting connective tissue growth factor (ctgf)EXCALIARD PHARMACEUTICALS INC·Filed 2015·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →